Type A Botulinum toxin

today NCT00213577 · Ph 2

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00213577	Dec 2003 → Sep 2007	overactive bladder	University Hospital, Rouen	Terminated	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT02325063 Comparator	Dec 2015 → May 2017	epicondylitis	Nîmes University Hospital	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Type A Botulinum toxin	“Patients will be treated with an injection of Type A Botulinum toxin.” NCT02325063 ↗ 1 NCT00213577 ↗
Known as	BoNTA	“Botulinum toxin type A (BoNTA) has been reported to be effective for treatment of patients with neurogenic detrusor overactivity (NDO) refractory to anticholinergic agents.” PMID 20674149 ↗ Jul 2010
Known as	Botulinum toxin type A	“Botulinum toxin type A (BoNTA) has been reported to be effective for treatment of patients with neurogenic detrusor overactivity (NDO) refractory to anticholinergic agents.” PMID 20674149 ↗ Jul 2010
Known as	type A botulinic toxin	“Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment” NCT00213577 ↗
Known as	Xeomin	“Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).” NCT02325063 ↗
Route	Other	“intradetrusor injection” PMID 20674149 ↗ Jul 2010